▶ Specification : 10%
▶ Category : Skeletal muscle relaxant
Chloroxazone 200mg
Adults : Orally administer 200 to 400mg chloroxazone 3 to 4 times daily.
Increase or reduce according to age and symptoms.
Painful spasm accompanying musculoskeletal disease : lumbodorsal pain, shoulder-arm syndrome, peritendinitis of the shoulders, deforming spondylosis
1. Warnings
There are reports of rare severe (sometime fatal) liver cell toxicity in patients administered this drug. The mechanism is now known but idiosyncratic and cannot be predicted. Immediately discontinue administration if fever, rash, loss of appetite, nausea, vomiting, fatigue, migraine, hematuria, jaundice, or elevated AST, ALT, ALP or bilirubin appear, and consult a physician if symptoms are exacerbated. For patients with a history of liver disease, consult a physician before administering.
2. Do not administer to the following patients
1) Patients with a history of hypersensitivity to this drug
2) Patients with no tolerance for this drug
3) This drug contains lactose. Do not administer to patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
3. Administer carefully to the following patients.
1) Patients with liver or renal impairment
2) Patients with allergic reaction to drugs or a history thereof
4. Adverse reactions
1) Hypersensitivity : Discontinue administration if rashes, itchiness, or hives, etc. appear.
2) Psychoneural : Take appropriate action such as reduction of dose or discontinuation if sleepiness, dizziness, staggering, malaise, or hyperstimulation appear.
3) Liver : Rarely, renal impairment may appear. Observe sufficiently and discontinue administration if anomalies appear.
4) Digestive system : Nausea and vomiting, heartburn, gastric stasis, stomach discomfort, diarrhea, constipation, epigastric pain, stomach pain, rarely gastroenteric bleeding.
5) Misc. : Rarely allergic skin rashes, petechial hemorrhage, ecchymosis, angioneurotic edema, anaphylactic reaction and discoloration of urine due to phenol metabolites of this drug may appear.
5. General precautions
May cause sleepiness and reduced concentration, attention and reflexes; patients taking this drug should not operate dangerous machinery such as cars.
6. Interactions
Concomitant administration with the following or alcohol consumption may increase interactions. Avoiding concomitant administration is preferable, but carefully administer when inevitable, reducing dose as necessary : phenothiazine drugs (chlorpromazine, etc.), central nervous system depressants (barbital drugs, etc.), MAO inhibitors
7. Administration to pregnant women and nursing mothers
1) Safety not established for administration during pregnancy; only administer to pregnant or potentially pregnant women when benefits of treatment outweigh risks.
2) When administering to nursing mothers, discontinue breast feeding.
8. Administration to children
Safety not established for infants and children; only administer when benefits of treatment outweigh risks.
9. Administration to elderly patients
Elderly patients generally have reduced physiological functions; administer with caution, reducing dose as necessary.
Chloroxazone 200mg
Adults : Orally administer 200 to 400mg chloroxazone 3 to 4 times daily.
Increase or reduce according to age and symptoms.
Painful spasm accompanying musculoskeletal disease : lumbodorsal pain, shoulder-arm syndrome, peritendinitis of the shoulders, deforming spondylosis
1. Warnings
There are reports of rare severe (sometime fatal) liver cell toxicity in patients administered this drug. The mechanism is now known but idiosyncratic and cannot be predicted. Immediately discontinue administration if fever, rash, loss of appetite, nausea, vomiting, fatigue, migraine, hematuria, jaundice, or elevated AST, ALT, ALP or bilirubin appear, and consult a physician if symptoms are exacerbated. For patients with a history of liver disease, consult a physician before administering.
2. Do not administer to the following patients
1) Patients with a history of hypersensitivity to this drug
2) Patients with no tolerance for this drug
3) This drug contains lactose. Do not administer to patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
3. Administer carefully to the following patients.
1) Patients with liver or renal impairment
2) Patients with allergic reaction to drugs or a history thereof
4. Adverse reactions
1) Hypersensitivity : Discontinue administration if rashes, itchiness, or hives, etc. appear.
2) Psychoneural : Take appropriate action such as reduction of dose or discontinuation if sleepiness, dizziness, staggering, malaise, or hyperstimulation appear.
3) Liver : Rarely, renal impairment may appear. Observe sufficiently and discontinue administration if anomalies appear.
4) Digestive system : Nausea and vomiting, heartburn, gastric stasis, stomach discomfort, diarrhea, constipation, epigastric pain, stomach pain, rarely gastroenteric bleeding.
5) Misc. : Rarely allergic skin rashes, petechial hemorrhage, ecchymosis, angioneurotic edema, anaphylactic reaction and discoloration of urine due to phenol metabolites of this drug may appear.
5. General precautions
May cause sleepiness and reduced concentration, attention and reflexes; patients taking this drug should not operate dangerous machinery such as cars.
6. Interactions
Concomitant administration with the following or alcohol consumption may increase interactions. Avoiding concomitant administration is preferable, but carefully administer when inevitable, reducing dose as necessary : phenothiazine drugs (chlorpromazine, etc.), central nervous system depressants (barbital drugs, etc.), MAO inhibitors
7. Administration to pregnant women and nursing mothers
1) Safety not established for administration during pregnancy; only administer to pregnant or potentially pregnant women when benefits of treatment outweigh risks.
2) When administering to nursing mothers, discontinue breast feeding.
8. Administration to children
Safety not established for infants and children; only administer when benefits of treatment outweigh risks.
9. Administration to elderly patients
Elderly patients generally have reduced physiological functions; administer with caution, reducing dose as necessary.
